300750 Contemporary Amperex Technology (A)

DGAP-News: EBD Group: Europe's largest annual life sciences partnering conference convenes in Hamburg for its 25th anniversary

DGAP-News: EBD Group / Key word(s): Conference
EBD Group: Europe's largest annual life sciences partnering conference convenes in Hamburg for its 25th anniversary

29.08.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


 

Europe's largest annual life sciences partnering conference convenes in Hamburg for its 25th anniversary

Carlsbad, CA and Hamburg, Germany - August 28, 2019: The 25th annual  global life science partnering event will be held November 11-13, 2019, in Hamburg, Germany, supported by regional hosts Life Science Nord, the City of Hamburg, and the State of Schleswig-Holstein. The event is expected to bring together 4,400 executives from 2,300+ life science companies spanning an estimated 60+ countries to engage in one-to-one partnering.

"We are excited that Hamburg has been chosen to host BIO-Europe for the third time," said Hinrich Habeck, Managing Director of the Northern German cluster organization Life Science Nord. "Hamburg is all about connecting, having more bridges than any other place in Europe. In line with this great tradition, Life Science Nord builds bridges to connect its 500 companies, research facilities and institutions to create a truly innovative and hands-on community. Our particular strength is the whole value chain of drug development, which is why we are delighted to have great partners like Evotec, Nordmark, Eppendorf, and Indivumed in our regional host committee at this year's BIO-Europe."

"We are pleased to be hosted by one of Europe's most important locations for life sciences, the Life Science Nord Cluster of Hamburg and Schleswig-Holstein," said Anna Chrisman, Group Managing Director, EBD Group. "This life science cluster employs over 49,000 people in the biotech, pharma and medtech fields, with internationally renowned research institutes and universities producing ground-breaking research in unmet medical needs, making it the perfect setting for the discovery and deal making that takes place at BIO-Europe to further global drug development."

BIO-Europe is a "must-attend" event for executives from the global biotechnology industry who will gain direct access to service and manufacturing partners, innovative assets, and ideas from biotech companies ranging from very early stage to large, established companies. The event is also a critical business strategy for biotech companies to meet with pharma executives and investors to propel their drug development commercialization goals.

On this important 25th anniversary, BIO-Europe 2019 is sure to be the largest ever, and is already on track to surpass the size of the 2018 event. Last year's record 27,000 one-to-one partnering meetings were powered by EBD's industry-leading platform, partneringONE(R), which now has enhanced features for an even more robust experience, plus a responsive mobile component. In 2018 there were 5,203 licensing opportunities on offer, 139 company presentations and 131 exhibitors.

for BIO-Europe 2019 by August 30, 2019 and save EUR 200 off the regular registration rate.

For news and interviews with executives and thought leaders in the life science industry, go to EBD Group's .

# # #

Additional links and information:

Follow BIO-Europe 2019 on Twitter: (hashtag: #BIOEurope)

About EBD Group

EBD Group's overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, , that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.

Today our events (BIO-Europe(R), BIO-Europe Spring(R), BioPharm America(TM), Biotech Showcase(TM), China Showcase, Digital Medicine & Medtech Showcase, ChinaBio(R) Partnering Forum, Rare Disease Innovation and Partnering Summit, Cell & Gene Meeting on the Med, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

Tune into EBD Group's Partnering Insight for timely coverage of news that influences the business strategies of the life science industry. EBD Group is an Informa company. For more information please visit.

Media contact:

Kari Bennett, EBD Group: ;

European media support:

Anne Hennecke, MC Services AG: 22;

 



29.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


864399  29.08.2019 

fncls.ssp?fn=show_t_gif&application_id=864399&application_name=news&site_id=research_pool
EN
29/08/2019

Underlying

300750Contemporary Amperex Technology (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Contemporary Amperex Technology (A)

 PRESS RELEASE

DGAP-News: ADL Bionatur Solutions Wins New Fermentation Client With Co...

DGAP-News: ADL Bionatur Solutions / Key word(s): Agreement ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million 02.12.2019 / 09:06 The issuer is solely responsible for the content of this announcement. ADL BIONATUR SOLUTIONS WINS NEW FERMENTATION CLIENT WITH CONTRACT REVENUES OF EUR 20 MILLION The agreement with a leading Swiss biotech company includes technology transfer, upscaling and industrial-scale production of high value-added innovative ingredients for the cosmetics and nutrition industry ADL to apply its expertise in a...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: Dozens Savings Plc 5.00% Secured Bonds due 2 December 2020 ISIN: GB00BL1GTZ11  Symbol: DS04 EMS: 1 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   W...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: SAPO PLC Ordinary Shares of GBP 0.01 ISIN: GB00B16GQJ90 Symbol: SAPO EMS: 5000 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   Website: ...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publishes open letter to Dr. Martin Haefner...

EQS Group-News: Dynamics Group AG / Key word(s): Statement/Corporate Action LIWET HOLDING AG publishes open letter to Dr. Martin Haefner in various Swiss Sunday newspapers 01.12.2019 / 05:59 Open letter to Dr. Martin Haefner Dear Mr Haefner We share your concern about the future of Schmolz+Bickenbach (S+B). The company urgently needs money, everyone - including Liwet - agrees. However, there is still time to find a constructive solution for S+B that is in the interest of all, not only one particular shareholder. Liwet is ready to rescue the company and the 10,000 jobs. Liw...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haef...

EQS Group-News: Dynamics Group AG / Schlagwort(e): Stellungnahme/Kapitalmaßnahme LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haefner in verschiedenen Schweizer Sonntagszeitungen 01.12.2019 / 05:59 Offener Brief an Dr. Martin Haefner Sehr geehrter Herr Haefner Wir teilen Ihre Sorge um die Zukunft von Schmolz+Bickenbach (S+B). Die Firma braucht dringend Geld; damit sind alle - auch Liwet - einverstanden. Noch bleibt Zeit, um eine konstruktive Lösung für S+B zu finden, die im Interesse aller Aktionäre ist, nicht nur eines einzigen. Liwet steht bereit, die Fir...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch